메뉴 건너뛰기




Volumn 47, Issue 3, 2008, Pages 147-152

Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin?

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; VANCOMYCIN;

EID: 42949085893     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-200847030-00001     Document Type: Article
Times cited : (34)

References (27)
  • 1
    • 0033504530 scopus 로고    scopus 로고
    • Bacteremic pneumonia due to staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms
    • Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29: 1171-7
    • (1999) Clin Infect Dis , vol.29 , pp. 1171-1177
    • Gonzalez, C.1    Rubio, M.2    Romero-Vivas, J.3
  • 2
    • 0242552187 scopus 로고    scopus 로고
    • Linezolid vs vancomycin: Analysis of two double-blind studies of patients with methicillin-resistant staphylococcus aureus nosocomial pneumonia
    • Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97
    • (2003) Chest , vol.124 , pp. 1789-1797
    • Wunderink, R.G.1    Rello, J.2    Cammarata, S.K.3
  • 3
    • 0034021097 scopus 로고    scopus 로고
    • Treatment of gram-positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin
    • Fagon J, Patrick H, Haas DW, et al. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. Am J Respir Crit Care Med 2000; 161: 753-62
    • (2000) Nosocomial Pneumonia Group. Am J Respir Crit Care Med , vol.161 , pp. 753-762
    • Fagon, J.1    Patrick, H.2    Haas, D.W.3
  • 4
    • 0035112879 scopus 로고    scopus 로고
    • Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
    • Rubinstein E, Cammarata S, Oliphant T, et al. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-12
    • (2001) Clin Infect Dis , vol.32 , pp. 402-412
    • Rubinstein, E.1    Cammarata, S.2    Oliphant, T.3
  • 5
    • 13644269309 scopus 로고    scopus 로고
    • Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia
    • American Thoracic Society, Infectious Diseases Society of America
    • American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416
    • (2005) Am J Respir Crit Care Med , vol.171 , pp. 388-416
  • 6
    • 33645662696 scopus 로고    scopus 로고
    • Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant staphylococcus aureus pneumonia
    • Scheetz MH, Wunderink RG, Postelnick MJ, et al. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy 2006; 26: 539-50
    • (2006) Pharmacotherapy , vol.26 , pp. 539-550
    • Scheetz, M.H.1    Wunderink, R.G.2    Postelnick, M.J.3
  • 7
    • 33947116497 scopus 로고    scopus 로고
    • What does it mean: Appropriate therapy for methicillin-resistant staphylococcus aureus? [letter]
    • Viale P, Pea F. What does it mean: appropriate therapy for methicillin-resistant Staphylococcus aureus? [letter]. Crit Care Med 2007; 35: 991
    • (2007) Crit Care Med , vol.35 , pp. 991
    • Viale, P.1    Pea, F.2
  • 8
    • 3242688631 scopus 로고    scopus 로고
    • Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: Influence of disease severity
    • Clec'h C, Timsit JF, De Lassence A, et al. Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 2004; 30: 1327-33
    • (2004) Intensive Care Med , vol.30 , pp. 1327-1333
    • Clec'h, C.1    Timsit, J.F.2    De Lassence, A.3
  • 9
    • 30144434179 scopus 로고    scopus 로고
    • Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: Maximizing clinical outcomes and minimizing selection of resistant organisms
    • Niederman MS. Use of broad-spectrum antimicrobials for the treatment of pneumonia in seriously ill patients: maximizing clinical outcomes and minimizing selection of resistant organisms. Clin Infect Dis 2006; 42 Suppl. 2: S72-81
    • (2006) Clin Infect Dis , vol.42 , Issue.SUPPL. 2
    • Niederman, M.S.1
  • 10
    • 24944459102 scopus 로고    scopus 로고
    • Pneumonia caused by oxacillin-resistant staphylococcus aureus treated with glycopeptides
    • Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33: 1983-7
    • (2005) Crit Care Med , vol.33 , pp. 1983-1987
    • Rello, J.1    Sole-Violan, J.2    Sa-Borges, M.3
  • 11
    • 33644598029 scopus 로고    scopus 로고
    • Methicillin-resistant staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy
    • Shorr AF, Combes A, Kollef MH, et al. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 2006; 34: 700-6
    • (2006) Crit Care Med , vol.34 , pp. 700-706
    • Shorr, A.F.1    Combes, A.2    Kollef, M.H.3
  • 12
    • 33744823760 scopus 로고    scopus 로고
    • The antimicrobial therapy puzzle: Could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?
    • Pea F, Viale P. The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients? Clin Infect Dis 2006; 42: 1764-71
    • (2006) Clin Infect Dis , vol.42 , pp. 1764-1771
    • Pea, F.1    Viale, P.2
  • 13
    • 33645118294 scopus 로고    scopus 로고
    • Effects of prolonged vancomycin administration on methicillin-resistant staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia
    • Sakoulas G, Gold HS, Cohen RA, et al. Effects of prolonged vancomycin administration on methicillin-resistant Staphylococcus aureus (MRSA) in a patient with recurrent bacteraemia. J Antimicrob Chemother 2006; 57: 699-704
    • (2006) J Antimicrob Chemother , vol.57 , pp. 699-704
    • Sakoulas, G.1    Gold, H.S.2    Cohen, R.A.3
  • 14
    • 29244442296 scopus 로고    scopus 로고
    • The pharmacokinetic and pharmacodynamic properties of vancomycin
    • Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis 2006; 42 Suppl. 1: S35-9
    • (2006) Clin Infect Dis , vol.42 , Issue.SUPPL. 1
    • Rybak, M.J.1
  • 15
    • 7444254040 scopus 로고    scopus 로고
    • Pharmacodynamics of vancomycin and other antimicrobials in patients with staphylococcus aureus lower respiratory tract infections
    • Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42
    • (2004) Clin Pharmacokinet , vol.43 , pp. 925-942
    • Moise-Broder, P.A.1    Forrest, A.2    Birmingham, M.C.3
  • 16
    • 0027499255 scopus 로고
    • Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients
    • Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37: 281-6
    • (1993) Antimicrob Agents Chemother , vol.37 , pp. 281-286
    • Lamer, C.1    De Beco, V.2    Soler, P.3
  • 17
    • 33644853958 scopus 로고    scopus 로고
    • Monitoring of vancomycin serum levels for the treatment of staphylococcal infections
    • Kitzis MD, Goldstein FW. Monitoring of vancomycin serum levels for the treatment of staphylococcal infections. Clin Microbiol Infect 2006; 12: 92-5
    • (2006) Clin Microbiol Infect , vol.12 , pp. 92-95
    • Kitzis, M.D.1    Goldstein, F.W.2
  • 18
    • 25144470553 scopus 로고    scopus 로고
    • Antimicrobial therapy in critically ill patients: A review of pathophysiological conditions responsible for altered disposition and phar-macokinetic variability
    • Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and phar-macokinetic variability. Clin Pharmacokinet 2005; 44: 1009-34
    • (2005) Clin Pharmacokinet , vol.44 , pp. 1009-1034
    • Pea, F.1    Viale, P.2    Furlanut, M.3
  • 19
    • 0034119630 scopus 로고    scopus 로고
    • Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function: Multiple daily doses may be preferable
    • Pea F, Poz D, Baraldo M, et al. Optimisation of vancomycin regimen in neutropenic haematological patients with normal renal function: multiple daily doses may be preferable. Clin Drug Invest 2000; 19: 213-8
    • (2000) Clin Drug Invest , vol.19 , pp. 213-218
    • Pea, F.1    Poz, D.2    Baraldo, M.3
  • 20
    • 34247611015 scopus 로고    scopus 로고
    • Pharmacodynamics of antibiotics to treat multidrug-resistant grampositive hospital infections
    • Pea F, Viale P. Pharmacodynamics of antibiotics to treat multidrug-resistant Grampositive hospital infections. Expert Rev Anti Infect Ther 2007; 5: 255-70
    • (2007) Expert Rev Anti Infect Ther , vol.5 , pp. 255-270
    • Pea, F.1    Viale, P.2
  • 21
    • 33750950323 scopus 로고    scopus 로고
    • Increased vancomycin MICs for staphylococcus aureus clinical isolates from a university hospital during a 5-year period
    • Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol 2006; 44: 3883-6
    • (2006) J Clin Microbiol , vol.44 , pp. 3883-3886
    • Wang, G.1    Hindler, J.F.2    Ward, K.W.3
  • 22
    • 17944367778 scopus 로고    scopus 로고
    • Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: Prospective multicenter randomized study
    • Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7
    • (2001) Antimicrob Agents Chemother , vol.45 , pp. 2460-2467
    • Wysocki, M.1    Delatour, F.2    Faurisson, F.3
  • 23
    • 24944499018 scopus 로고    scopus 로고
    • MRSA pneumonia: Better outcome through continuous infusion of vancomycin?
    • Blot S. MRSA pneumonia: better outcome through continuous infusion of vancomycin? Crit Care Med 2005; 33: 2127-8
    • (2005) Crit Care Med , vol.33 , pp. 2127-2128
    • Blot, S.1
  • 24
    • 0031702762 scopus 로고    scopus 로고
    • Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant staphylococcus aureus and enterococcus faecalis
    • Klepser ME, Patel KB, Nicolau DP, et al. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy 1998; 18: 1069-74
    • (1998) Pharmacotherapy , vol.18 , pp. 1069-1074
    • Klepser, M.E.1    Patel, K.B.2    Nicolau, D.P.3
  • 25
    • 33750082642 scopus 로고    scopus 로고
    • Predictors of mortality for methicillinresistant staphylococcus aureus health-care-associated pneumonia: Specific evaluation of vancomycin pharmacokinetic indices
    • Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillinresistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: 947-55
    • (2006) Chest , vol.130 , pp. 947-955
    • Jeffres, M.N.1    Isakow, W.2    Doherty, J.A.3
  • 26
    • 33750285524 scopus 로고    scopus 로고
    • High-dose vancomycin therapy for methicillinresistant staphylococcus aureus infections: Efficacy and toxicity
    • Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillinresistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44
    • (2006) Arch Intern Med , vol.166 , pp. 2138-2144
    • Hidayat, L.K.1    Hsu, D.I.2    Quist, R.3
  • 27
    • 33750137089 scopus 로고    scopus 로고
    • Management of persistent bacteremia caused by methicillin-resistant staphylococcus aureus: A survey of infectious diseases consultants
    • Hageman JC, Liedtke LA, Sunenshine RH, et al. Management of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus: a survey of infectious diseases consultants. Clin Infect Dis 2006; 43: e42-5
    • (2006) Clin Infect Dis , vol.43
    • Hageman, J.C.1    Liedtke, L.A.2    Sunenshine, R.H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.